GO
Loading...

Bristol-Myers Squibb Co

More

  • July 24- Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma. Sales of Eliquis, which Bristol-Myers co-markets with Pfizer Inc, rose to $171 million.

  • NEW YORK, July 24- Major global stock markets edged higher while the euro rose from an eight-month low against the U.S. dollar on Thursday following upbeat euro zone data and stronger-than-expected U.S. earnings.

  • Ford earnings, jobless claims to lift Wall Street Thursday, 24 Jul 2014 | 8:40 AM ET

    U.S. stock index futures rose on Thursday, ahead of one of the heaviest days for U.S. and European second-quarter earnings.

  • Politics fade as earnings take over Friday, 18 Jul 2014 | 6:30 PM ET
    Espirito Santo International is the parent company of several institutions, including Banco Espirito Santo.

    Even as traders monitor the world's hot spots, corporate earnings news could be a positive for stocks in the week ahead.

  • Cramer’s Bristol-Myers theorem: What is it? Monday, 7 Jul 2014 | 6:28 PM ET

    You always hear Cramer shouting about Bristol – Maaah-yerss. Why is that?

  • July 1- Bristol-Myers Squibb Co said it was voluntarily recalling six lots of the injectable version of its blood thinner, Coumadin, in the United States, after particulate matter was found in some unreleased samples.

  • Early movers: NKE, DD, PFE, GM, INTC, BMY & more Friday, 27 Jun 2014 | 7:33 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • NEW YORK, June 25- U.S. stock investors ignored weak economic data and pushed equities higher on Wednesday, as drugmakers' shares rose and a Supreme Court ruling lifted major broadcaster stocks, while German bond yields hit the year's low on safe-haven bids.

  • US STOCKS-Wall St gains with drugmakers, broadcasters Wednesday, 25 Jun 2014 | 5:09 PM ET

    *Monsanto rallies on outlook and stock-repurchase plans. *CBS shares jump after Supreme Court ruling. Shares of CBS jumped 6.2 percent to $62.48 after the U.S. Supreme Court ruled that online TV startup Aereo Inc violates copyright law by using tiny antennas to provide subscribers with broadcast network content via the Internet.

  • US stocks finish higher; S&P 500 near record close Wednesday, 25 Jun 2014 | 4:51 PM ET
    Trader on the floor of the New York Stock Exchange.

    U.S. stocks rose on Wednesday after mixed economic reports.

  • US STOCKS-Wall St rises slightly despite weak GDP report Wednesday, 25 Jun 2014 | 1:40 PM ET

    *Monsanto rallies after results; General Mills lower. *Medical Action almost doubles, Owens& Minor to buy.

  • Midday movers: CBS, HBI, MON, BMY, MDCI & More Wednesday, 25 Jun 2014 | 11:28 AM ET

    Take a look at some of Wednesday's midday movers.

  • US STOCKS-Wall St edges higher despite weak GDP report Wednesday, 25 Jun 2014 | 10:27 AM ET

    *Monsanto rallies after results, General Mills lower. NEW YORK, June 25- U.S. stocks edged higher on Wednesday as investors continued to find value in equities over other asset classes despite the latest economic data coming in below expectations.

  • *Investors watching Iraq violence; crude prices rise. *Monsanto rallies after results, General Mills lower. NEW YORK, June 25- U.S. stock index futures pointed to a lower open on Wednesday as the latest economic data came in below expectations, giving investors further reasons to take profits amid ongoing tension in Iraq.

  • US STOCKS-Futures flat after decline, GDP data awaited Wednesday, 25 Jun 2014 | 7:39 AM ET

    *Investors watching Iraq tension, crude oil rises early. Durable goods orders, also due at 8:30 a.m., are seen as flat in May, while a June read on service sector business activity from financial data firm Markit is seen as essentially unchanged from May.

  • June 24- A late-stage trial testing Bristol-Myers Squibb Co's cancer immunotherapy nivolumab in advanced melanoma patients was halted early after it was determined that the drug was likely to prolong survival, the company said on Tuesday.

  • Check out which companies are making headlines after the bell Tuesday.

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire flagged the promise of existing and new drugs on Monday as evidence that AbbVie's $46 billion offer undervalued the company, the latest British firm to be targeted by a U.S. group seeking lower taxes.

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire flagged the promise of existing and new drugs on Monday as evidence that AbbVie's $46 billion offer undervalued the company, the latest British firm to be targeted by a U.S. group seeking lower taxes.

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire is to take a leaf out of AstraZeneca's playbook by giving long-range forecasts for its drugs as it seeks to convince shareholders that AbbVie's $46 billion offer undervalues the business.